NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** 19 August 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Mark Kroese (Chair) Present for all items
2. Keith Abrams Present for all items
3. Liz Adair Present for all items
4. John Cairns Present for all items
5. Jim Gray Present for all items
6. Patrick McGinley Present for all items
7. Ross Maconachie Present for all items
8. Alexandria Moseley Present for all items
9. Karen Sennett Present for all items
10. Brian Shine Present for all items
11. Matt Stevenson Present for all items

NICE staff present

Sarah Byron, Programme Director Present for all items

Rebecca Albrow, Associate Director Present for all items

Suvi Harmala, Technical Analyst Present for all items

Donna Barnes, Project Manager Present for all items

Alex Sexton, Administrator Present for all items

External assessment group representatives present

Isaac Corroramos, Health Economics Researcher Present for items 1 – 4.1.7
Kleijnen Systematic Reviews Ltd (KSR)

Marie Westwood, Reviews Manager Present for items 1 – 4.1.7
Kleijnen Systematic Reviews Ltd (KSR)

Specialist Committee Members present

Matthew Brookes, Consultant Gastroenterologist, Present for all items
Royal Wolverhampton NHS Trust

Fahmid Chowdhury, Consultant Radiologist Present for all items
& Nuclear Medicine Physician,
Leeds Teaching Hospitals NHS Trust

Mark Follows, Clinical Lead Planned Present for all items
Care/ Gastroenterology, Norfolk and Waveney CCG

Nigel Horwood, Lay specialist committee Present for all items
member

Yvonne McKenzie, Specialist Dietician Present for all items

John McLaughlin, Professor of Gastroenterology Present for all items
and Nutrition, University of Manchester
and Salford Royal Hospitals

Karen Slade, Lay specialist committee Present for all items
member

Peter Whorwell, Professor of Medicine Present for all items
and Gastroenterology, Wythenshawe Hospital

Observers present

Sarah Bromley, Senior Medical Editor, NICE Present for all items

Jacob Grant, Technical Analyst, NICE Present for all items

Rosalee Mason, Coordinator, NICE Present for all items

Ian Mather, Business Analyst, NICE Present for all items

Vera Unwin, Technical Analyst, NICE Present for all items

## Minutes

### Introduction to the meeting

* 1. The Chair welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from standing committee members Rebecca Allcock, Sam Creavin, Diane Davies, Neil Hawkins, Michael Messenger, Shelley Rahman Hayley and Alasdair Taylor. There were no apologies from specialist committee members.

### News and announcements

* 1. The Chair noted that Ross Maconachie was leaving the Diagnostics Advisory Committee due to a change in role and thanked him for all his work and valuable contributions during his time as a member of the Committee.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 15 June 2021.

### Evaluation of SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea

* 1. Part 1 – Open session
		1. The Chair welcomed external assessment group representatives, members of the public and company representatives from General Electric Healthcare.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered. The following standing committee members had notified these interests in advance of the meeting:
* Keith Abrams declared financial interests as he is a Partner and Director, Visible Analytics Limited, a HTA consultancy company, but he has not been involved in any projects which involve a diagnostic technology. He also declared a non-financial professional and personal interest as since 2017 he has funding to support an MRC Industrial PhD Studentship from Swiss Precision Diagnostics / Clearblue for a project on prediction of early miscarriage. It was agreed these interests would not prevent Keith Abrams from participating in the meeting.
* John Cairns declared financial interests as he has been advising Astellas on health economic modelling for roxadustat for treating anaemia in people with chronic kidney disease (since October 2020) and advising Takeda on economic evaluation of maribavir (during August 2021). It was agreed that these interests would not prevent John Cairns from participating in the meeting.
* Sam Creavin declared a financial interest in that he is a GP Partner in an NHS practice. It was agreed that this interest would not prevent Sam Creavin from participating in the meeting.
* Patrick McGinley declared a financial interest as he is a Faculty Member of MTech Access, providing updates on the NHS finance regime and the impact of these changes to MTech Access and receive an honorarium for this. He also declared non-financial professional and personal interests as he is a Strategic Council member of the All-Party Parliamentary Group (APPG) on Obesity, providing advice on costs of the disease within NHS to the APPG. He is also the Hon Treasurer for the Association for Study of Obesity (ASO), and a member of the Obesity Policy Engagement Network UK (OPEN UK). It was agreed that these interests would not prevent Patrick McGinley from participating in the meeting.
* Ross Maconachie declared a non-financial personal and professional interest in the meeting in that he is employed by Merck Sharp & Dohme Limited (MSD). As far as he is aware MSD do not make any drugs that could be used to treat bile acid diarrhoea. It was agreed that this interest would not prevent Ross Maconachie from participating in the meeting.

The following specialist committee members had notified these interests in advance of the meeting:

* Matthew Brookes declared financial interests due to earnings from private practice. He had received honoraria for an advisory board from Vifor Pharma (in 2019), and from Abbvie Pharma (in 2017). He also declared non-financial professional and personal interests in that he was Chief Investigator on a study to determine validity of faecal bile acid testing (interest ceased 2020), he was a Trustee of Guts UK! Charity (interest ceased 2019), was research chair for the British Society of Gastroenterology (interest ceased 2019), and is currently a member of the IBD UK Board. He also declared indirect interests as his research department has received grant funding from Tillotts Pharma (interest ceased 2020), and from Vifor Pharma (interest ceased 2020), and will receive grant funding from Norgine. It was agreed these interests would not prevent Matthew Brookes from participating in the meeting.
* Fahmid Chowdhury declared the following financial interests: national PET/CT contract reporting and auditing, Alliance Medical Limited; director, F&S Medical Imaging (12532293); designated member, Leeds Radiology Group (OC411908). He also declared receipt of speaker honoraria from GE Healthcare Limited, for presenting at reporter workshops about quantification of DaTSCAN in Parkinsonian syndromes (interest ceased 2020). It was agreed these interests would not prevent Fahmid Chowdhury from participating in the meeting.
* Mark Follows declared a financial interest due to funding from Reckitt Benckiser Healthcare for Upper GI Educational Hub RCGP/ Pulse GP training (interest ceased in 2019). It was agreed this interest would not prevent Mark Follows from participating in the meeting.
* Nigel Horwood declared a financial interest as he had been paid a nominal sum for patient and public involvement (PPI) work by Motilent in 2017. He also declared non-financial personal and professional interests as he is the patient representative on Guy’s and St Thomas’ Gastro Project Board; joint PPI lead on Osiris (optimising shared decision-making for high-risk major surgery) funded by the National Institute of Health Research (NIHR) and is involved with various studies being sponsored by Bowel Cancer UK charity. It was agreed these interests would not prevent Nigel Horwood from participating in the meeting.
* Yvonne McKenzie declared a financial interest as she is a clinical dietitian undertaking private practice. She also declared non- financial professional and personal interests due to her research project, ‘effectiveness of non-pharmacological therapies in the management of bile acid diarrhoea in adults: a protocol for a systematic review’ [https://www.crd.york.ac.uk/prospero/
display\_record.php?RecordID=188328](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=188328). She is the Clinical Lead in IBS for the Gastroenterology Specialist Group of the British Dietetic Association. It was agreed these interests would not prevent Yvonne McKenzie from participating in the meeting.
* John McLaughlin declared non-financial professional and personal interests as in 2015-16 he co-chaired the NICE-funded multicentre prospective survey of SeHCAT provision and practice in the UK led by KITEC and subsequently published (Summers et al). He also declared that he is an active member of the UK Bile Acid Related Diarrhoea Network of clinicians and researchers, a trustee for Research and Deputy Clinical Chair, Guts UK charity, and Head of Division, Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, University of Manchester. It was agreed these interests would not prevent John McLaughlin from participating in the meeting.
* Peter Whorwell declared financial interests as he undertakes private practice. He has or had research funding from EnteroMed ltd (ongoing), 4D Pharma (ceased 2019), Ironwood Pharmaceuticals (ceased 2018), Danone (ceased 2018), and Salix Pharmaceuticals (ceased 2016). He was on an advisory board for Allergan UK (ceased 2019). He also declared non-financial professional and personal interests as he is an advisor to the IBS Network, an advisor to the International Foundation for Functional Gastrointestinal Disorders USA, and a member of the Rome International Working Team on Functional Gastrointestinal Disorders. It was agreed these interests would not prevent Peter Whorwell from participating in the meeting.
	+ 1. The Committee proceeded to discuss the comments made during the public consultation for the ‘SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea’ topic.
		2. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
		3. The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.
		4. The Chair thanked the manufacturer representatives, the EAG and public observers for their attendance at the meeting.
		5. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
	1. Part 2 - Closed session
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Diagnostics Guidance Document (DGD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Diagnostics Guidance Document (DGD) in line with their decisions.

### Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (DAC) will be held on Thursday 16 September 2021.